MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Publicacións (398) Publicacións de MIGUEL JOSÉ MARTÍN JIMÉNEZ
2024
-
Breast cancer risk for the joint exposure to metals and metalloids in women: Results from the EPIC-Spain cohort
The Science of the total environment, Vol. 912, pp. 168816
-
Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)
Clinical and Translational Oncology
2023
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90
-
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer, Vol. 184, pp. 48-59
-
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428
-
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400
-
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 2
2022
-
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634
-
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
Frontiers in Oncology, Vol. 12
-
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
BMC Psychiatry, Vol. 22, Núm. 1
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293
-
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
The Lancet Oncology, Vol. 23, Núm. 3, pp. 382-392
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Code of practice needed for samples donated by trial participants
The Lancet Oncology
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
-
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
Breast Cancer Research and Treatment
-
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
Frontiers in Oncology, Vol. 12